Jianchuan Deng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2359781/publications.pdf

Version: 2024-02-01

1684188 1474206 10 118 5 9 citations g-index h-index papers 10 10 10 96 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Experimental and Molecular Medicine, 2022, 54, 194-205.	7.7	39
2	Clusterization in acute myeloid leukemia based on prognostic alternative splicing signature to reveal the clinical characteristics in the bone marrow microenvironment. Cell and Bioscience, 2020, 10, 118.	4.8	9
3	Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092763.	3.2	5
4	Development of an immuneâ€related prognostic model for pediatric acute lymphoblastic leukemia patients. Molecular Genetics & Genomic Medicine, 2020, 8, e1404.	1.2	6
5	Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review). Molecular and Clinical Oncology, 2020, 13, 95-100.	1.0	9
6	Comprehensive analysis the potential biomarkers for the high-risk of childhood acute myeloid leukemia based on a competing endogenous RNA network. Blood Cells, Molecules, and Diseases, 2019, 79, 102352.	1.4	15
7	A six-gene-based prognostic model predicts complete remission and overall survival in childhood acute myeloid leukemia /p>. OncoTargets and Therapy, 2019, Volume 12, 6591-6604.	2.0	29
8	Decreased expression of the augmenter of liver regeneration results in growth inhibition and increased chemosensitivity of acute T lymphoblastic leukemia cells. Oncology Reports, 2017, 38, 3130-3136.	2.6	2
9	Establishment and primary clinical application of competitive inhibition for measurement of augmenter of liver regeneration. Experimental and Therapeutic Medicine, 2014, 7, 93-96.	1.8	4
10	The Combination of Anti-Thymocyte Globulin and Basiliximab for Haploidentical Hematopoietic Stem Cell Transplantation. Integrative Journal of Medical Sciences, 0, 8, .	0.0	0